1988
founding of curasan^® Pharma GmbH
launch of local anaesthetics
market introduction of antibiotics

1996
founding of curasan^® Benelux

1997
registration of Cerasorb^® for dentistry and maxillofacial surgery

1998
start of clinical studies with Cerasorb^®
launch of Hy-GAG^®
founding of liaison office Austria

1999
first clinical results on Cerasorb^®
founding of curasan branch in France
launch of a method for the production of platelet rich plasma (PRP) from patient blood

2000
Innovation Award for Cerasorb^®
transformation into a public company (curasan AG ) and Initial Public Offering (IPO)

2001
acquisition of Titanium Innovations
acquisition of Pro-tec Medizinische Produkte GmbH
launch of stypro^®
upgrading of R&D and production center in Frankfurt

2002
FDA-approval for Cerasorb^® Ortho™ for use in orthopedics and traumatology
CE-approval for Cerasorb^® block forms

2003
Product launch of Cerasorb^® Ortho™ in the USA
FDA-approval of Cerasorb^® block forms in the USA
FDA-certification of Cerasorb^® production site
Sale of pharmaceuticals business

2004
founding of curasan, Inc., USA for the dental market
product launch of Cerasorb^® M
merging of GerontoCare and Titanium Innovations GmbH with curasan AG

2005
product launch Curavisc^® (curasan Benelux)

2006
product launch REVOIS^® All-in-One Dental Implant System

2008
Sale of the then existing dental division to RIEMSER ARZNEITMITTEL AG
Received Japanese patent for bone regeneration material Cerasorb^® M

2009
CE-certification of ATR^® and Osbone^®
Founding of new curasan Inc, the US subsidiary to focus on the orthopedic, spine, and trauma market
Transfer of curasan AG stock from Prime Standard to General Standard

2010
Worldwide product launch of Osbone^®, the new synthetic spongious hydroxyapatite bone subsitute of non-biologic origin